Tags

Type your tag names separated by a space and hit enter

Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease.
Trends Endocrinol Metab. 2020 10; 31(10):773-784.TE

Abstract

Gender difference is well recognized as a key risk factor for cardiovascular disease (CVD). Estrogen, the primary female sex hormone, improves cardiovascular functions through receptor (ERα, ERβ, or G protein-coupled estrogen receptor)-initiated genomic or non-genomic mechanisms. Gaseous signaling molecules, including nitric oxide (NO), hydrogen sulfide (H2S), and carbon monoxide (CO), are important regulators of cardiovascular function. Recent studies have demonstrated that estrogen regulates the production of these signaling molecules in cardiovascular cells to exert its cardiovascular protective effects. We discuss current understanding of gaseous signaling molecules in cardiovascular disease (CVD), the underlying mechanisms through which estrogen exerts cardiovascular protective effects by regulating these molecules, and how these findings can be translated to improve the health of postmenopausal women.

Authors+Show Affiliations

Department of Gynecology and Obstetrics, Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Key Laboratory of Cardiovascular Diseases, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511518, P.R. China; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, P.R. China.Department of Gynecology and Obstetrics, Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Key Laboratory of Cardiovascular Diseases, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511518, P.R. China; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, P.R. China.Molecular and Cellular Gynecological Endocrinology Laboratory (MCGEL), Department of Reproductive Medicine and Child Development, University of Pisa, Pisa 56100, Italy.Department of Gynecology and Obstetrics, Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Key Laboratory of Cardiovascular Diseases, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511518, P.R. China; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, P.R. China. Electronic address: dongxing.zhu@gzhmu.edu.cn.Department of Gynecology and Obstetrics, Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Key Laboratory of Cardiovascular Diseases, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511518, P.R. China; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, P.R. China. Electronic address: fuxiaod@gzhmu.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32682630

Citation

Teoh, Jian-Peng, et al. "Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease." Trends in Endocrinology and Metabolism: TEM, vol. 31, no. 10, 2020, pp. 773-784.
Teoh JP, Li X, Simoncini T, et al. Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease. Trends Endocrinol Metab. 2020;31(10):773-784.
Teoh, J. P., Li, X., Simoncini, T., Zhu, D., & Fu, X. (2020). Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease. Trends in Endocrinology and Metabolism: TEM, 31(10), 773-784. https://doi.org/10.1016/j.tem.2020.06.001
Teoh JP, et al. Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease. Trends Endocrinol Metab. 2020;31(10):773-784. PubMed PMID: 32682630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Estrogen-Mediated Gaseous Signaling Molecules in Cardiovascular Disease. AU - Teoh,Jian-Peng, AU - Li,Xiaosa, AU - Simoncini,Tommaso, AU - Zhu,Dongxing, AU - Fu,Xiaodong, Y1 - 2020/07/15/ PY - 2020/04/10/received PY - 2020/06/07/revised PY - 2020/06/22/accepted PY - 2020/7/20/pubmed PY - 2021/8/4/medline PY - 2020/7/20/entrez KW - carbon monoxide KW - cardiovascular disease KW - estrogen KW - gaseous signaling molecules KW - hydrogen sulfide KW - nitric oxide SP - 773 EP - 784 JF - Trends in endocrinology and metabolism: TEM JO - Trends Endocrinol Metab VL - 31 IS - 10 N2 - Gender difference is well recognized as a key risk factor for cardiovascular disease (CVD). Estrogen, the primary female sex hormone, improves cardiovascular functions through receptor (ERα, ERβ, or G protein-coupled estrogen receptor)-initiated genomic or non-genomic mechanisms. Gaseous signaling molecules, including nitric oxide (NO), hydrogen sulfide (H2S), and carbon monoxide (CO), are important regulators of cardiovascular function. Recent studies have demonstrated that estrogen regulates the production of these signaling molecules in cardiovascular cells to exert its cardiovascular protective effects. We discuss current understanding of gaseous signaling molecules in cardiovascular disease (CVD), the underlying mechanisms through which estrogen exerts cardiovascular protective effects by regulating these molecules, and how these findings can be translated to improve the health of postmenopausal women. SN - 1879-3061 UR - https://www.unboundmedicine.com/medline/citation/32682630/Estrogen_Mediated_Gaseous_Signaling_Molecules_in_Cardiovascular_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-2760(20)30133-8 DB - PRIME DP - Unbound Medicine ER -